These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2075 related articles for article (PubMed ID: 24552318)

  • 1. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Dignam JJ; Armstrong TS; Wefel JS; Blumenthal DT; Vogelbaum MA; Colman H; Chakravarti A; Pugh S; Won M; Jeraj R; Brown PD; Jaeckle KA; Schiff D; Stieber VW; Brachman DG; Werner-Wasik M; Tremont-Lukats IW; Sulman EP; Aldape KD; Curran WJ; Mehta MP
    N Engl J Med; 2014 Feb; 370(8):699-708. PubMed ID: 24552317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
    N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
    Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
    Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS
    Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.
    Muni R; Minniti G; Lanzetta G; Caporello P; Frati A; Enrici MM; Marchetti P; Enrici RM
    Tumori; 2010; 96(1):60-4. PubMed ID: 20437859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
    N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
    Magnuson W; Ian Robins H; Mohindra P; Howard S
    J Neurooncol; 2014 Mar; 117(1):133-9. PubMed ID: 24469853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab and daily temozolomide for recurrent glioblastoma.
    Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
    Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3 trial of bevacizumab in ovarian cancer.
    Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
    N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
    Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
    J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
    Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
    Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis.
    Erpolat OP; Akmansu M; Goksel F; Bora H; Yaman E; Büyükberber S
    Tumori; 2009; 95(2):191-7. PubMed ID: 19579865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
    J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
    Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 104.